The burgeoning field of innate immune-mediated disease and autoinflammation

Journal of Pathology

Volumn 241, Issue 2, 2017, Pages 123-139

  Peckham, Daniel ^a   Scambler, Thomas ^a   Savic, Sinisa ^a   McDermott, Michael F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

autoinflammation; autoinflammatory; cystic fibrosis; IFN; infection; inflammasome; inflammation; innate immunity; NLRP3; proteasome; pyrin

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PYRIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

AICARDI GOUTIERES SYNDROME; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; AUTOPHAGY; BLAU SYNDROME; CINCA SYNDROME; CYSTIC FIBROSIS; ENZYME ACTIVATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNE DYSREGULATION; IMMUNE MEDIATED INJURY; INNATE IMMUNITY; MUCKLE WELLS SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SCHNITZLER SYNDROME; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNFOLDED PROTEIN RESPONSE; ANIMAL; AUTOIMMUNE DISEASE; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; INFLAMMATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; AUTOPHAGY; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMASOMES; INFLAMMATION;

EID: 85000349738     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4812     Document Type: Review

References (162)

1. Bernard C. Leçons sur les phénomènes de la vie communs aux animaux et aux végétaux. Libraire J-B, Baillière et Fils: Paris, 1878; 404–564.
2. Aksentijevich I, Centola M, Deng Z, et al., Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90: 797–807.
3. Bernot A, Clepet C, Dasilva C, et al. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25–31.
4. de Jesus AA, Canna SW, Liu Y, et al. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 2015; 33: 823–874.
5. Savic S, Dickie LJ, Wittmann M, et al. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 2012; 26: 505–533.
6. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133–144.
7. McDermott MF, Aksentijevich I. The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2002; 2: 511–516.
8. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 2006; 305: 127–160.
9. Ciccarelli F, De Martinis M, Ginaldi L. An update on autoinflammatory diseases. Curr Med Chem 2014; 21: 261–269.
10. Stoffels M, Kastner DL. Old dogs, new tricks: monogenic autoinflammatory disease unleashed. Annu Rev Genomics Hum Genet 2016; 17: 245–272.
11. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: 1242–1248.
12. Weatherall DJ. Pharmacological treatment of monogenic disease. Pharmacogenomics J 2003; 3: 264–266.
13. Drenth JPH, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999; 22: 178–181.
14. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22: 175–177.
15. Canna SW, Goldbach-Mansky R. New monogenic autoinflammatory diseases – a clinical overview. Semin Immunopathol 2015; 37: 387–394.
16. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 2002; 10: 417–426.
17. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat Genet 2001; 29: 301–305.
18. Dodé C, Le Dû N, Cuisset L, et al. New mutations of CIAS1 that are responsible for Muckle–Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 2002; 70: 1498–1506.
19. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheumatol 2002; 46: 2445–2452.
20. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002; 71: 198–203.
21. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheumatol 2002; 46: 3340–3348.
22. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N Engl J Med 2003; 348: 2583–2584.
23. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581–592.
24. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheumatol 2005; 52: 1283–1286.
25. Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis 2016; DOI: 10.1136/annrheumdis-2015-209031; 17: 245–272.
26. van der Hilst JCH, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial mediterranean fever: a systematic review of the literature. Biologics 2016; 10: 75–80.
27. Savic S, Dickie LJ, Battellino M, et al. Familial mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 2012; 24: 103–112.
28. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426–2437.
29. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620–628.
30. Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89: 432–437.
31. Wulffraat NM, Woo P. Canakinumab in pediatric rheumatic diseases. Expert Opin Biol Ther 2013; 13: 615–622.
32. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416–2425.
33. Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep 2014; 16: 398
34. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol 2008; 58: 1505–1515.
35. Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25: 469–484.
36. Saito M, Fujisawa A, Nishikomori R, et al. Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheumatol 2005; 52: 3579–3585.
37. Shinar Y, Tohami T, Livneh A, et al. Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis. Orphanet J Rare Dis 2015; 10: 86.
38. Rowczenio DM, Trojer H, Omoyinmi E, et al. Association of tumor necrosis factor receptor-associated periodic syndrome with gonosomal mosaicism of a novel 24-nucleotide TNFRSF1A deletion. Arthritis Rheumatol 2016; 68: 2044–2049.
39. Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 cause Aicardi–Goutières syndrome at the AGS1 locus. Nat Genet 2006; 38: 917–920.
40. Volpi S, Picco P, Caorsi R, et al. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J 2016; 14: 35.
41. Crow YJ. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr Opin Immunol 2015; 32: 7–12.
42. Stetson DB, Ko JS, Heidmann T, et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134: 587–598.
43. Rice GI, Bond J, Asipu A, et al. Mutations involved in Aicardi–Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41: 829–832.
44. Rice GI, Rodero MP, Crow YJ. Human disease phenotypes associated with mutations in TREX1. J Clin Immunol 2015; 35: 235–243.
45. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79: 731–737.
46. Rice GI, Del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014; 46: 503–509.
47. Savic S, McDermott MF. Clinical genetics in 2014: new monogenic diseases span the immunological disease continuum. Nat Rev Rheumatol 2015; 11: 67–68.
48. Sullivan KE, Stiehm ER. Stiehm's Immune Deficiencies. 2014.
49. Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheumatol 2012; 64: 895–907.
50. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507–518.
51. van Kempen TS, Wenink MH, Leijten EF, et al. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol 2015; 11: 483–492.
52. Wu J, Li X, Zhu G, et al. The role of Resveratrol-induced mitophagy/autophagy in peritoneal mesothelial cells inflammatory injury via NLRP3 inflammasome activation triggered by mitochondrial ROS. Exp Cell Res 2016; 341: 42–53.
53. Abdelaziz DH, Khalil H, Cormet-Boyaka E, et al. The cooperation between the autophagy machinery and the inflammasome to implement an appropriate innate immune response: do they regulate each other? Immunol Rev 2015; 265: 194–204.
54. Jabir MS, Hopkins L, Ritchie ND, et al. Mitochondrial damage contributes to Pseudomonas aeruginosa activation of the inflammasome and is downregulated by autophagy. Autophagy 2015; 11: 166–182.
55. Liu L, Yang M, Kang R, et al. HMGB1–DNA complex-induced autophagy limits AIM2 inflammasome activation through RAGE. Biochem Biophys Res Commun 2014; 450: 851–856.
56. Cho MH, Cho K, Kang HJ, et al. Autophagy in microglia degrades extracellular beta-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 2014; 10: 1761–1775.
57. Rodgers MA, Bowman JW, Liang Q, et al. Regulation where autophagy intersects the inflammasome. Antioxid Redox Signal 2014; 20: 495–506.
58. Shi H, Zhang Z, Wang X, et al. Inhibition of autophagy induces IL-1beta release from ARPE-19 cells via ROS mediated NLRP3 inflammasome activation under high glucose stress. Biochem Biophys Res Commun 2015; 463: 1071–1076.
59. Agyemang AF, Harrison SR, Siegel RM, et al. Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond. Semin Immunopathol 2015; 37: 335–347.
60. Bachetti T, Chiesa S, Castagnola P, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2013; 72: 1044–1052.
61. Bachetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. J Mol Med (Berl) 2014; 92: 583–594.
62. Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12: 863–875.
63. Luciani A, Villella VR, Esposito S, et al. Cystic fibrosis: a disorder with defective autophagy. Autophagy 2014; 7: 104–106.
64. Luciani A, Villella VR, Esposito S, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 cystic fibrosis transmembrane conductance regulator. Autophagy 2012; 8: 1657–1672.
65. Assani K, Tazi MF, Amer AO, et al. IFN-gamma stimulates autophagy-mediated clearance of Burkholderia cenocepacia in human cystic fibrosis macrophages. PLoS One 2014; 9: e96681.
66. Al-Khodor S, Marshall-Batty K, Nair V, et al. Burkholderia cenocepacia J2315 escapes to the cytosol and actively subverts autophagy in human macrophages. Cell Microbiol 2014; 16: 378–395.
67. Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 2015; 125: 4196–4211.
68. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 2039.
69. Elborn JS. Cystic fibrosis. Lancet 2016; DOI: 10.1016/S0140-6736(16)00576-6.
70. Grassmé H, Carpinteiro A, Edwards MJ, et al. Regulation of the inflammasome by ceramide in cystic fibrosis lungs. Cell Physiol Biochem 2014; 34: 45–55.
71. Tang A, Sharma A, Jen R, et al. Inflammasome-mediated IL-1β production in humans with cystic fibrosis. PLoS One 2012; 7: e37689.
72. Becker KA, Grassmé H, Zhang Y, et al. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell Physiol Biochem 2010; 26: 57–66.
73. Dixey J, Redington AN, Butler RC, et al. The arthropathy of cystic fibrosis. Ann Rheum Dis 1988; 47: 218–223.
74. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111–2118.
75. Horsley A, Helm J, Brennan A, et al. Gout and hyperuricaemia in adults with cystic fibrosis. J R Soc Med 2011; 104(suppl 1): S36–S39.
76. Garnett JP, Nguyen TT, Moffatt JD, et al. Proinflammatory mediators disrupt glucose homeostasis in airway surface liquid. J Immunol 2012; 189: 373–380.
77. Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6: 101–109.
78. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–241.
79. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13: 160–166.
80. Rajamaki K, Nordstrom T, Nurmi K, et al. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem 2013; 288: 13410–13419.
81. Ribeiro CM, Boucher RC. Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses. Proc Am Thorac Soc 2010; 7: 387–394.
82. Tosco A, De Gregorio F, Esposito S, et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ 2016; 23: 1380–1393.
83. Saitoh T, Akira S. Regulation of inflammasomes by autophagy. J Allergy Clin Immunol 2016; 138: 28–36.
84. Choi AJ, Ryter SW. Autophagy in inflammatory diseases. Int J Cell Biol 2011; 2011: 732798.
85. Zhang PX, Cheng J, Zou S, et al. Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nat Commun 2015; 6: 6221.
86. Iannitti RG, Napolioni V, Oikonomou V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun 2016; 7: 10791.
87. Touitou I, Lesage S, McDermott M, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Human Mut 2004; 24: 194–198.
88. Canna SW, De Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014; 46: 1140–1146.
89. Pathak S, McDermot M, Savic S. Autoinflammatory diseases: update on classification diagnosis and management. J Clin Pathol 2016; DOI: 10.1136/jclinpat-2016-203810 (in press).
90. Blohmke CJ, Mayer ML, Tang AC, et al. Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses. J Immunol 2012; 189: 5467–5475.
91. Fitch G, Williams K, Freeston JE, et al. Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy. J Cyst Fibros 2016; 15: e35-e40.
92. Ng HP, Zhou Y, Song K, et al. Neutrophil-mediated phagocytic host defense defect in myeloid Cftr-inactivated mice. PloS One 2014; 9: e106813.
93. Pohl K, Hayes E, Keenan J, et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Blood 2014; 124: 999–1009.
94. Su X, Looney MR, Su HE, et al. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. Inflamm Res 2011; 60: 619–632.
95. Tirouvanziam R, Gernez Y, Conrad CK, et al. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci USA 2008; 105: 4335–4339.
96. Chan HC, Jiang XH, Ruan YC. Emerging role of cystic fibrosis transmembrane conductance regulator as an epigenetic regulator: linking environmental cues to microRNAs. Clin Exp Pharmacol Physiol 2014; 41: 615–622.
97. Said-Sadier N, Padilla E, Langsley G, et al. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS One 2010; 5: e10008.
98. Moriyama M, Chen IY, Kawaguchi A, et al. The RNA- and TRIM25-binding domains of influenza virus NS1 protein are essential for suppression of NLRP3 inflammasome-mediated interleukin-1beta secretion. J Virol 2016; 90: 4105–4114.
99. Triantafilou K, Kar S, van Kuppeveld FJ, et al. Rhinovirus-induced calcium flux triggers NLRP3 and NLRC5 activation in bronchial cells. Am J Respir Cell Mol Biol 2013; 49: 923–934.
100. Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93–98.
101. Etherington C, Naseer R, Conway SP, et al. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J. Cyst Fibros 2014; 13: 49–55.
102. Flight WG, Bright-Thomas RJ, Tilston P, et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax 2014; 69: 247–253.
103. Allen IC, Scull MA, Moore CB, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30: 556–565.
104. Gavrilin MA, Abdelaziz DH, Mostafa M, et al. Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 2012; 188: 3469–3477.
105. Abdulrahman BA, Abu Khweek A, Akhter A, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011; 7: 1359–1370.
106. Di Lorenzo F, Silipo A, Bianconi I, et al. Persistent cystic fibrosis isolate Pseudomonas aeruginosa strain RP73 exhibits an under-acylated LPS structure responsible of its low inflammatory activity. Mol Immunol 2015; 63: 166–175.
107. Martinon F, Chen X, Lee AH, et al. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 2010; 11: 411–418.
108. Qiu Q, Zheng Z, Chang L, et al. Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis. EMBO J 2013; 32: 2477–2490.
109. Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208: 519–533.
110. Dickie LJ, Aziz AM, Savic S, et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012; 71: 2035–2043.
111. 2+ store expansion is mediated by X-box binding protein-1. J Biol Chem 2009; 284: 14904–14913.
112. 2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis. Nat Commun 2015; 6: 6201.
113. Abais JM, Xia M, Zhang Y, et al. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal 2015; 22: 1111–1129.
114. Hernandez ML, Mills K, Almond M, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol Pract 2015; 135: 379–385.
115. Tang A, Sharma A, Jen R, et al. Inflammasome-mediated IL-1beta production in humans with cystic fibrosis. PLoS One 2012; 7: e37689.
116. Bronner DN, Abuaita BH, Chen X, et al. Endoplasmic reticulum stress activates the inflammasome via NLRP3- and caspase-2-driven mitochondrial damage. Immunity 2015; 43: 451–462.
117. Lubamba BA, Jones LC, O'Neal WK, et al. X-box-binding protein 1 and innate immune responses of human cystic fibrosis alveolar macrophages. Am J Respir Crit Care Med 2015; 192: 1449–1461.
118. Savic S, Ouboussad L, Dickie LJ, et al. TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. J Autoimmun 2014; 50: 59–66.
119. Bodar EJ, van der Hilst JCH, Drenth JPH, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005; 63: 260–264.
120. Campbell L, Raheem I, Malemud CJ, et al. The relationship between NALP3 and autoinflammatory syndromes. Int J Mol Sci 2016; 17:725.
121. Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (UK) 2012; 51: 1855–1859.
122. Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016; 17: 914–921.
123. Wittmann M, Kingsbury SR, McDermott MF. Is caspase 1 central to activation of interleukin-1? Joint Bone Spine 2011; 78: 327–330.
124. Celsi F, Piscianz E, Romano M, et al. Knockdown of MVK does not lead to changes in NALP3 expression or activation. J Inflamm 2015; 12:e1–e5.
125. Jurczyluk J, Munoz MA, Skinner OP, et al. Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases. Immunology and Cell Biology 2016; DOI: 10.1038/icb.2016.58 (in press).
126. Bento CF, Puri C, Moreau K, et al. The role of membrane-trafficking small GTPases in the regulation of autophagy. J Cell Sci 2013; 126: 1059–1069.
127. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014; 513: 237–241.
128. Harris J, Hartman M, Roche C, et al. Autophagy controls IL-1β secretion by targeting Pro-IL-1β for degradation. J Biol Chem 2011; 286: 9587–9597.
129. Shi CS, Shenderov K, Huang NN, et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13: 255–263.
130. Wolf AJ, Reyes CN, Liang W, et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell 2016; 166: 624–636.
131. Poulton KR, Nightingale S. A new metabolic muscle disease due to abnormal hexokinase activity. J Neurol Neurosurg Psychiatry 1988; 51: 250–255.
132. Wang ZV, Deng Y, Gao N, et al. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell 2014; 156: 1179–1192.
133. Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014; 515: 431–435.
134. Kong F, Ye B, Lin L, et al. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytes. Biomed Pharmacother 2016; 82: 167–172.
135. Mimura N, Fulciniti M, Gorgun G, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012; 119: 5772–5781.
136. Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21: 248–255.
137. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21: 263–269.
138. Yang JL, Xu H, Shao F. The immunological function of familial Mediterranean fever disease protein Pyrin. Sci China Life Sci 2014; 57: 1156–1161.
139. Masters SL, Lagou V, Jéru I, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med 2016; 8:332ra345.
140. Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2015; 48: 67–73.
141. Wartz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004; 430: 694–699.
142. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet's disease: a comprehensive review. J Autoimmun 2015; 64: 137–148.
143. Zhou Q, Xiaomin Y, Demirkaya E, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci USA 2016; 113: 10127–10132.
144. Jéru I, Cochet E, Duquesnoy P, et al. Involvement of TNFRSF11A molecular defects in autoinflammatory disorders. Arthritis Rheumatol 2014; 66: 2621–2627.
145. Jo EK, Kim JK, Shin DM, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 2016; 13: 148–159.
146. Walker UA, Hoffman HM, Williams R, et al. Severe inflammation following vaccination against Streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol 2016; 68: 516–520.
147. Iyer S, He Q, Janczy J, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 2013; 39: 311–323.
148. Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 2009; 106: 20388–20393.
149. Lawlor KE, Khan N, Mildenhall A, et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 2015; 18: 6282.
150. Alarcón-Riquelme ME. Nucleic acid by-products and chronic inflammation. Nat Genet 2006; 38: 866–867.
151. Dennis Jr G, Holweg CTJ, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 2014; 16: R90.
152. Lenart N, Brough D, Denes A. Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab 2016 36: 1668–1685.
153. Abderrazak A, Syrovets T, Couchie D, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 2015; 4: 296–307.
154. Ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74: 1636–1644.
155. Sarrabay G, Touitou I. Autoinflammation: management of hereditary recurrent fevers – SHARE experience. Nat Rev Rheumatol 2015; 11: 567–569.
156. Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012; 366: 330–338.
157. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014; 345: 1623–1627.
158. Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol 2016; 17: 495–504.
159. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370: 911–920.
160. Elkan PN, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370: 921–931.
161. Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity. Curr Opin Rheumatol 2013; 25: 234–240.
162. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121–141.